Reported 5 months ago
The article discusses CRISPR Therapeutics' potential as a wealth generator for investors, particularly due to its gene therapy for hereditary blood diseases and promising pipeline programs. While the company is expected to experience growth and potentially become profitable in the future, the article notes that due to its current market size, it may not offer millionaire-making returns for a $10,000 investment, requiring a larger investment and more time. Despite this, CRISPR Therapeutics could still be a valuable addition to a long-term investor's portfolio.
Source: YAHOO